{"id":"ozurdex-drug-implant-product","safety":{"commonSideEffects":[{"rate":"26","effect":"Cataract progression"},{"rate":"27","effect":"Elevated intraocular pressure"},{"rate":"16","effect":"Conjunctival hemorrhage"},{"rate":"15","effect":"Floaters"},{"rate":"8","effect":"Eye pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The implant releases dexamethasone, a potent corticosteroid, over an extended period (approximately 3 months) into the vitreous cavity. This localized delivery suppresses inflammatory cytokines and reduces macular edema and inflammation associated with various retinal conditions. The sustained-release formulation allows for prolonged therapeutic effect with a single intravitreal injection.","oneSentence":"Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:28.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Macular edema following retinal vein occlusion"},{"name":"Macular edema associated with uveitis"},{"name":"Diabetic macular edema"}]},"trialDetails":[{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04082962","phase":"PHASE1","title":"Dexamethasone Implant for Retinal Detachment in Uveal Melanoma","status":"COMPLETED","sponsor":"Ivana K. Kim","startDate":"2018-12-11","conditions":"Exudative Retinal Detachment and Uveal Melanoma","enrollment":10},{"nctId":"NCT05023304","phase":"PHASE4","title":"In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Vance Thompson Vision","startDate":"2021-08-23","conditions":"Cataract","enrollment":30},{"nctId":"NCT06536491","phase":"PHASE1, PHASE2","title":"EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema","status":"RECRUITING","sponsor":"Eclipse Life Sciences, Inc.","startDate":"2024-08-19","conditions":"Diabetic Macular Edema","enrollment":75},{"nctId":"NCT06429306","phase":"PHASE3","title":"Study of Dexycu in Treating Intraocular Inflammation","status":"COMPLETED","sponsor":"Ocumension Therapeutics (Shanghai) Co., Ltd","startDate":"2022-08-22","conditions":"Inflammation, Cataract","enrollment":285},{"nctId":"NCT04396990","phase":"PHASE4","title":"The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study","status":"COMPLETED","sponsor":"Vance Thompson Vision","startDate":"2020-06-08","conditions":"Refractive Surgery","enrollment":20},{"nctId":"NCT04411693","phase":"PHASE4","title":"Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-04-10","conditions":"Diabetic Macular Edema","enrollment":23},{"nctId":"NCT04462523","phase":"PHASE4","title":"DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery","status":"COMPLETED","sponsor":"Patrick R. Oellers, MD","startDate":"2020-01-03","conditions":"Vitreo-Retinal Surgery","enrollment":40},{"nctId":"NCT04976777","phase":"PHASE3","title":"A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-10-12","conditions":"Macular Edema","enrollment":54},{"nctId":"NCT02556424","phase":"PHASE3","title":"Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2016-01","conditions":"Inflammatory Macular Edema","enrollment":114},{"nctId":"NCT04619303","phase":"PHASE4","title":"Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO","status":"COMPLETED","sponsor":"Lions Eye Institute, Perth, Western Australia","startDate":"2017-02-07","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":59},{"nctId":"NCT04549935","phase":"PHASE4","title":"The PRIME Study: A Randomized, Controlled, Prospective Study","status":"RECRUITING","sponsor":"Vance Thompson Vision - MT","startDate":"2020-09-14","conditions":"Patient Preference, Patient Outcomes, Post-Operative Inflammation","enrollment":20},{"nctId":"NCT03889444","phase":"","title":"Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-01-15","conditions":"Diabetic Macular Edema","enrollment":141},{"nctId":"NCT04038125","phase":"PHASE4","title":"Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME","status":"UNKNOWN","sponsor":"Retina Macula Specialists of Miami, LLC","startDate":"2019-08-22","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia","enrollment":20},{"nctId":"NCT01788475","phase":"NA","title":"Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2013-02-22","conditions":"Diabetic Macular Edema","enrollment":3},{"nctId":"NCT04281862","phase":"PHASE4","title":"DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery","status":"UNKNOWN","sponsor":"Vance Thompson Vision","startDate":"2020-01-23","conditions":"Refractive Surgery","enrollment":20},{"nctId":"NCT02479555","phase":"PHASE2","title":"Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization","status":"UNKNOWN","sponsor":"Mercator MedSystems, Inc.","startDate":"2016-01","conditions":"Chronic Limb Ischemia","enrollment":120},{"nctId":"NCT02479620","phase":"PHASE2","title":"Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization","status":"UNKNOWN","sponsor":"Mercator MedSystems, Inc.","startDate":"2016-06","conditions":"Chronic Limb Ischemia","enrollment":120},{"nctId":"NCT03629210","phase":"PHASE2","title":"Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Pradeepa Yoganathan","startDate":"2019-09","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02049476","phase":"PHASE4","title":"Study of the Effectiveness of Ozurdex for the Control of Uveitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-01","conditions":"Uveitis, Intermediate, Uveitis, Posterior","enrollment":20},{"nctId":"NCT03999125","phase":"PHASE4","title":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME","status":"UNKNOWN","sponsor":"Sudhalkar Eye Hospital","startDate":"2019-06-25","conditions":"Clinically Significant Macular Edema Due to Diabetes Mellitus","enrollment":150},{"nctId":"NCT00799227","phase":"PHASE2","title":"Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01-01","conditions":"Diabetic Macular Edema, Vitrectomy","enrollment":56},{"nctId":"NCT02684084","phase":"PHASE4","title":"Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema","status":"TERMINATED","sponsor":"North Toronto Eye Care Laser and Eye Specialists","startDate":"2015-11","conditions":"Diabetic Macular Edema","enrollment":5},{"nctId":"NCT01673191","phase":"PHASE2","title":"A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2012-11","conditions":"Macular Edema, Diabetes Mellitus","enrollment":40},{"nctId":"NCT01892163","phase":"PHASE3","title":"Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2013-03","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT01951066","phase":"PHASE2","title":"Diabetic Macular Edema Treated With Ozurdex (DMEO)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2013-10","conditions":"Diabetic Macular Edema","enrollment":20},{"nctId":"NCT02399657","phase":"PHASE4","title":"Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Inje University","startDate":"2015-02","conditions":"Diabetes Mellitus, Macular Edema, Retinal Exudates and Deposits","enrollment":48},{"nctId":"NCT01396057","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion","enrollment":244},{"nctId":"NCT01546402","phase":"PHASE4","title":"Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-05","conditions":"Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT01698788","phase":"NA","title":"Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-05","conditions":"Diabetic Macular Edema, Vision Disorders","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone"],"phase":"marketed","status":"active","brandName":"Ozurdex Drug Implant Product","genericName":"Ozurdex Drug Implant Product","companyName":"Sudhalkar Eye Hospital","companyId":"sudhalkar-eye-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ozurdex is a sustained-release dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye to reduce inflammation. Used for Macular edema following retinal vein occlusion, Macular edema associated with uveitis, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}